In the realm of medical research, the development of cutting-edge technologies has revolutionized our understanding and treatment of various diseases.

One such field is artificial intelligence (AI) neuroimaging detection and quantification, which may significantly impact the surveillance of Amyloid-Related Imaging Abnormalities (ARIA) that can be a side effect of recently approved pharmaceuticals being used to treat Alzheimer’s disease.